ClinicalTrials.gg
CompletedNCT01970163Updated Mar 14, 2018

DermACELL in Subjects With Chronic Wounds of the Lower Extremities

An interventional study of DermACELL and GraftJacket in Diabetic Foot Ulcer, sponsored by LifeNet Health. Completed at 12 sites in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-03-14.

Sponsored by LifeNet Health · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Enrollment
49th of 322
202 · median 60
Started
2013
with 19 others
No phase
186 of 381
38 open now
Registered
99th of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 49th largest by enrollment of the 322 interventional ones that give a count, is one of 20 that started in 2013, is one of 186 with no phase, and was the 99th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

The study will compare treatment with DermACELL to conventional care in diabetic foot ulcers (DFU) and venous stasis ulcers (VSU).

Read the detailed description

This study is designed to demonstrate the effectiveness of DermACELL in the treatment of chronic wounds of the lower extremities. DermACELL will be compared to conventional care in both subjects with diabetic foot ulcers (DFU) and subjects with venous stasis ulcers (VSU). In addition, DermACELL will be compared to an active comparator, GraftJacket, in subjects with diabetic foot ulcers.

DermACELL and GraftJacket are both made from donated human skin (dermis). These products have been processed so that cells are removed and bacteria and viruses are destroyed. This processing provided a supporting structure, an acellular dermal matrix, into which cells can migrate and divide during the wound healing process.

03

Conditions studied

  • Diabetic Foot Ulcer

Keywords

  • Diabetic foot ulcer
  • Venous stasis ulcer
  • Wound of the lower extremity
  • Skin substitute
  • Acellular Dermal Matrix
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female between the ages of 21 and 80 that are able to provide , are available for weekly clinic visits and are willing to comply with off-loading requirements of treatment;
  • If diabetic, have been on a stable dose of medication to treat diabetes for less than 30 days;
  • Have a DFU that has been present for at least 30 days or have a VSU that has been present for at least 60 days;

Exclusion criteria

Exclusion Criteria:

  • Have a DFU or VSU that is infected;
  • Are pregnant or lactating;
  • Have an allergy or are sensitive to one of the following antibiotics: lincomycin, gentamicin, polymyxin B, or vancomycin;
  • Have a sensitivity to polysorbate 20, N-lauroyl sarcosinate, benzonase or glycerol;
  • Have had a level greater than 12% within the past 90 days;
  • Have liver function tests or kidney function tests that are very elevated;
  • Have a known or suspected disease of the immune system;
  • Have had surgery in the past 30 days to increase blood flow into your leg or foot;
  • Have cancer or a connective tissue disease (i.e. lupus, rheumatoid arthritis);
  • Have undergone wound healing treatment with a living skin equivalent (i.e., Dermagraft®, Apligraf®, TheraSkin®, Oasis®, GraftJacket®, Integra®, Alloderm®) or topical growth factors in the last 4 weeks;
  • Have active Charcot disease, a weakening of the bones in the foot that can occur in people who have significant nerve damage (neuropathy);
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    DermACELL

    DermACELL acellular dermal matrix will be used to treat subjects diagnosed with an ulcer of the lower extremity (diabetic foot ulcer or venous stasis ulcer).

    Other: DermACELL

  • Placebo comparator
    Conventional care dressings

    Currently accepted standard of care wound management including Conventional care dressings will be utilized in subjects with a diagnosis of either diabetic foot ulcer or venous stasis ulcer.

    Other: Conventional Care Dressings

  • Active comparator
    GraftJacket

    GraftJacket acellular dermal matrix will be used in those subjects diagnosed with a diabetic foot ulcer.

    Other: GraftJacket

Interventions

  • OtherDermACELL

    Acellular dermal matrix is applied at Baseline visit. The study product may be reapplied an additional time (between Weeks 2 and 12 for venous stasis ulcers and between Weeks 3 and 12 for diabetic foot ulcers).

    Also known as: LifeNet Health Product Code: DCELL112

  • OtherGraftJacket

    Acellular dermal matrix applied at Baseline visit. May be reapplied one additional time during study (between Week 2 and 12 for venous stasis ulcers and Week 3 and 12 for diabetic foot ulcers).

    Also known as: KCI Product Code: GJ44

  • OtherConventional Care Dressings

    Depending on the state of the wound (dry or moist), different types of nonadherent dressings would be utilized as the primary dressing: * If the wound is dry, a nonadherent dressing, such an oil emulsion dressing, may be appropriate, as these dressings tend to donate moisture to the wound. * Hydrogels can also be used if the wound is in need of moisture. * For a wound that is more moist, a more absorptive dressing may be more appropriate to help reduce potential for maceration. A secondary dressing may be desired to add either loft or cushion.

06

What researchers measure

Primary outcomes

  1. Effect of DermACELL on the proportion of chronic wounds of the lower extremity that have healed.

    The primary outcome is the comparison of the proportion of chronic wounds treated with DermACELL and treated with conventional care that have achieved 100% re-epithelialization without dressing or drainage requirements at 12 weeks. Wound closure is defined as first observation of 100% re-epithelialization without drainage or dressing requirements and complete wound closure is defined as 100% re-epithelialization without dressing or drainage requirements confirmed at two consecutive study visits 2 weeks apart.

    Time frame: 12 weeks

Secondary outcomes

  1. Proportion of wounds closed at 12 weeks and weekly thereafter for up to 24 weeks

    The proportion of subjects with closed wounds at 12 weeks and weekly thereafter will be compared in subjects treated with DermACELL, GraftJacket (Diabetic foot ulcer subjects only) and conventional care wound management. A comparison of the proportion of subjects who received a second application of acellular dermal matrix will be made between the DermACELL and GraftJacket arms in those subjects with diabetic foot ulcers.

    Time frame: 24 weeks

Other outcomes

  1. Incidence of treatment-emergent adverse events (AE), changes in vital signs, ankle-brachial index (ABI) and physical examination findings.

    Safety of the interventions will be measured by the incidence of treatment-emergent AEs, changes in vital signs, ABI and physical examination.

    Time frame: 24 weeks

07

Study locations

12 sites
  • Institute for Advanced Wound Care
    Montgomery, Alabama 36111, United States
  • Southern Arizona VA Health Care System
    Tucson, Arizona 85723, United States
  • ILD Research Center
    Carlsbad, California 92009, United States
  • Center for Clinical Research
    Castro Valley, California 94546, United States
  • Limb Preservation Platform
    Fresno, California 93720, United States
  • Limb Preservation Platform
    Fresno, California 93721, United States
  • Fairfield County Foot Surgeons
    Norwalk, Connecticut 06851, United States
  • Andrews Research and Education Institute
    Gulf Breeze, Florida 32561, United States
  • Rosalind Franklin University, CLEAR
    North Chicago, Illinois 60064, United States
  • Boston Medical College
    Boston, Massachusetts 02118, United States
  • Wound Institute and Reseach Center
    Dunmore, Pennsylvania 18512, United States
  • VA Pittsburgh Healthcare System
    Pittsburgh, Pennsylvania 15240, United States
08

References and documents

Publications

  • Walters J, Cazzell S, Pham H, Vayser D, Reyzelman A. Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix Versus Conventional Care Wound Management and an Active Comparator in the Treatment of Full-Thickness Diabetic Foot Ulcers. Eplasty. 2016 Feb 4;16:e10. eCollection 2016. PubMed 26933467 ↗
  • Cazzell S, Vayser D, Pham H, Walters J, Reyzelman A, Samsell B, Dorsch K, Moore M. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair Regen. 2017 May;25(3):483-497. doi: 10.1111/wrr.12551. Epub 2017 Jun 12. PubMed 28544150 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Jan 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2013
First posted
Oct 25, 2013
Start
Oct 2013
Primary completionActual
Jan 2016
CompletionActual
Apr 2016
Last update
Mar 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01970163
Lead sponsor
LifeNet Health
Responsible party
Sponsor
First posted
Oct 25, 2013
Start date
Oct 2013
Primary completion
Jan 2016
Completion
Apr 2016
Last update
Mar 14, 2018

Study contacts

Mark Moore, Ph.D.
study director · LifeNet Health, Scientific Affairs

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion